Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-DOTA-LM3
- Development stage
- Unknown
- Lead developer
- University Hospital Basel
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
177Lu-DOTA-LM3 is an investigational radiopharmaceutical for peptide receptor radionuclide therapy (PRRT). It consists of the somatostatin receptor (SSTR) antagonist peptide DOTA-LM3 chelated to the beta-emitting radioisotope lutetium-177. The peptide targets somatostatin receptor subtype 2 (SSTR2), which is overexpressed on neuroendocrine tumor cells. In clinical studies, 177Lu-DOTA-LM3 has demonstrated favorable biodistribution, high tumor uptake, and prolonged retention compared to SSTR agonists, showing efficacy in patients with advanced metastatic neuroendocrine neoplasms (NENs), including those with low or no SSTR agonist binding.
- Other names
- 177Lu-LM3[177Lu]Lu-DOTA-LM3Lu-177-DOTA-LM3Lu177-DOTA-LM3Lu 177-DOTA-LM3lutetium (177Lu) DOTA-LM3lutetium-177 DOTA-LM3lutetium177 DOTA-LM3lutetium 177 DOTA-LM3
02
Targets
DNASSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on 177Lu-DOTA-LM3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-DOTA-LM3.